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summARY – germ-cell testicular cancer (gCTC) is a malignant neoplasm derived from the 
primordial germ cell. Although it accounts for approximately 1% of all malignancies in men, it is the 
most common cancer of younger male population, with the highest incidence between ages 15 and 35. 
Testicular cancer incidence rate has risen globally over the past several decades, with the average in-
crease in the incidence of testicular cancer in Croatia of 7% per annum from the year 1983 to 2007. 
Two main groups are seminomas and non-seminomas, each accounting for 50% of cases, and they 
differ in treatment modalities and response to therapy. Despite increase in the incidence rate, a prom-
ising circumstance is that gCTC has become a model of curable cancer. Because of advances in diag-
nostic procedures, sophisticated radiation techniques and especially the introduction of cisplatin based 
chemotherapy protocols together with advanced postchemotherapy surgical techniques, curability is 
expected in about 95% of all patients diagnosed with testicular cancer and over 70% of patients with 
advanced disease. in this review, we will focus on treatment strategies of primary gCTC.
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Introduction
germ-cell testicular cancer (gCTC) is a malig-
nant neoplasm derived from the primordial germ cell. 
it normally occurs inside the testicles, but in cases of 
errors during embryonal development (5 percent of 
cases) it can arise in extragonadal locations (cerebel-
lum, pineal gland, mediastinum, retroperitoneum). Al-
though it accounts for approximately 1% of all malig-
nancies in men, it is the most common cancer of 
younger male population, with the highest incidence 
between ages 15 and 351,2. According to the latest data 
from the Croatian national Cancer Registry from 
2014, the incidence rate of all newly diagnosed pa-
tients with testicular cancer was 9.4/100 000, with the 
highest incidence rate of 28/100 000 between the ages 
30 and 34 years3. Testicular cancer incidence rate has 
risen globally over the past several decades, with aver-
age increase in the incidence of testicular cancer in 
Croatia of 7% per annum from the year 1983 to 2007, 
with the projected increase in the incidence of testicu-
lar cancer of 72% by the year 20254,5.
The common influence of genetic predisposition 
and environmental factors plays a role in testicular 
cancer incidence rate upsurge. Contrary to current be-
liefs, there is no correlation between testicular cancer 
and testicular trauma, motorcycle driving, horseback 
riding, vasectomy, viral infections, or longer exposure 
to high temperatures2. The best characterized risk fac-
tor is cryptorchidism, where the earlier time of orchio-
pexy reduces the risk of testicular cancer. Another 
known risk factor is positive family history with 8-10 
fold increased risk in siblings of a person with testicu-
lar cancer and 4-6 fold in the son of a person with 
testicular cancer. in some other genetic disorders such 
as Klinefelter’s syndrome, Down’s syndrome and tes-
ticular dysgenesis syndrome, a higher rate of testicular 
cancer incidence is seen, as it is also seen in men diag-
nosed earlier with primary testicular cancer1.
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it is thought that tumorigenesis starts in primor-
dial germ cell that fails to differentiate into spermato-
gonia. This malignant transformation happens in utero 
and results in a precursor lesion known as intratubular 
germ-cell neoplasia (iTgCn)6. until the onset of tes-
ticular hormone changes during puberty, iTgCn 
does not have invasive potential. After hormonal and 
other yet unknown influences, iTgCn has the ability 
to develop into germinal and somatic malignant tis-
sues. seminoma is one of the main histologic types of 
gCTC, which is derived from transformed germ cell 
that resembles gonocyte, but is blocked in differentia-
tion. Another main type of gCTC is non-seminoma, 
which often consists of several other histologic sub-
types. The most undifferentiated type is embryonal 
carcinoma, which can go in extraembryonal differen-
tiation predisposing to choriocarcinoma and yolk sac 
tumor, or it can go in somatic differentiation predis-
posing to teratoma7,8. These two main groups, semino-
mas and non-seminomas, account for 50% of cases 
each, and differ in treatment modalities and response 
to therapy.
Despite increase in the incidence rate, a promising 
circumstance is that gCTC has become a model of 
curable cancer. Because of advances in diagnostic pro-
cedures, sophisticated radiation techniques, and espe-
cially the introduction of cisplatin based chemotherapy 
protocols together with advanced postchemotherapy 
surgical techniques, curability is expected in about 
95% of all patients diagnosed with testicular cancer 
and over 70% of patients with advanced disease9,10.
Diagnosis and Staging
Palpated scrotal mass is evaluated with scrotal ul-
trasonography, which should determine the etiology. 
Testicular cancer is described as a solid, hypoechoic 
mass. Testicular biopsy should never be performed be-
cause of the tumor seeding risk. measurement of beta 
subunit of human chorionic gonadotropin (bHCg), 
alpha fetoprotein (AfP) and lactate dehydrogenase 
(lDH) should help confirm the diagnosis. Raised 
lDH is not specific for germ-cell tumor; rather it is an 
indicator of disease volume11. Radical inguinal orchi-
ectomy with detailed histopathologic report on tumor 
histology, size, and presence or absence of lymphovas-
cular invasion is a diagnostic and therapeutic approach. 
Disease staging should be done with computed to-
mography imaging of the chest, abdomen and pelvis, 
and measurement of postorchiectomy tumor markers 
(bHCg, AfP and lDH). Testicular cancer is catego-
rized in three stages according to the American Joint 
Committee on Cancer, 8th edition (AJCC)12.




stage i is defined as a tumor limited to the testis, 
without retroperitoneal lymph node involvement or 
visceral metastases and with normal postorchiectomy 
serum tumor markers at primary diagnosis. About 
80% of patients are diagnosed at this stage, and the 
majority are cured with orchiectomy alone. following 
orchiectomy, the 5-year relapse rates are 15%-20%. 
Relapses are most likely to occur within the first two 
years after orchidectomy and relapse rate declines be-
yond the fifth year13. following orchiectomy, there are 
3 options recommended for the management of stage 
i seminoma, as follows: active surveillance, adjuvant 
treatment with radiotherapy to para-aortic lymph 
nodes, or adjuvant 1-2 cycles of chemotherapy with 
carboplatin, dosed at the area under the curve (AuC) 
of 712. The most encouraging fact is that in case of re-
lapse, the overall 5-year disease specific survival is 99%, 
independent of the 3 management options mentioned 
above1.
many groups have tried to investigate the risk fac-
tors in predicting relapse to ease identification of pa-
tients that should be allocated to active surveillance 
and those that should receive adjuvant treatment. Pri-
mary tumor size greater than 4 cm and rete testis inva-
sion have shown promising results as risk factors. in 
subsequent studies, there was insufficient evidence to 
support these findings, so the routine use of these pre-
dictive factors is not currently recommended9. on ac-
tive surveillance, there is a relapse rate of 20%12. This 
means that 80% of patients on active surveillance will 
be cured without any further treatment. With adjuvant 
radiotherapy or chemotherapy, they would be unneces-
sarily exposed to the potential acute and long term 
toxicities without improvement in overall survival. The 
goal of active surveillance is to spare 80% of patients of 
toxic treatments and in case of relapse, they can still be 
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cured in 99% of cases9. According to these data, active 
surveillance is the preferred option in relevant guide-
lines and in our Referral Center for Treatment of 
germ Cell Tumors and extragonadal germ Cell Tu-
mors in Croatia. The potential disadvantages of active 
surveillance are the lack of patient compliance and ex-
posure to imaging related radiation.
Alternatives to active surveillance are either adju-
vant radiotherapy or chemotherapy. in both options, 
the relapse rate after treatment is about 4%1. Although 
the dose and field of radiation was reduced over the 
past 20 years to 20 gy administered in 10 daily 2.0 
fractions to para-aortic and/or ipsilateral iliac lymph 
nodes, adjuvant radiotherapy in stage i seminoma has 
been abandoned in many major medical centers be-
cause of the long term risk of secondary malignancies 
and cardiovascular toxicity1,2. Adjuvant chemotherapy 
with 1-2 cycles of carboplatin dosed at the AuC of 7 
did not improve overall survival and due to added tox-
icity it is not the first option for patients who are will-
ing to undergo surveillance program9,15.
Seminoma stage II
stage ii is defined as a tumor that involves testis 
and retroperitoneal lymph nodes, without visceral me-
tastases and with normal or raised postorchiectomy 
serum tumor markers at primary diagnosis. About 
15% to 20% of patients diagnosed with seminoma are 
classified as having stage ii disease15. Postorchiectomy 
treatment options for stage ii seminoma include ra-
diotherapy to para-aortic and ipsilateral iliac lymph 
nodes to the cumulative dose of 30-36 gy, multi agent 
cisplatin based chemotherapy with 3 cycles of cisplat-
in, etoposide and bleomycin protocol (PeB protocol) 
or 4 cycles of cisplatin, etoposide protocol (Pe proto-
col). stage ii is divided by AJCC staging system based 
on the size of involved nodes into stage iiA (nodes <2 
cm), iiB (nodes 2-5 cm) and iiC (nodes >5 cm). for 
stage iiC, there is no debate about the indication for 
chemotherapy, but for iiA and iiB stages there are 
some differences among high-volume centers regard-
ing optimal choice of therapy16,17.
The national Comprehensive Cancer network 
(nCCn) testicular cancer guidelines treatment plan is 
based on dividing stage ii into low volume disease and 
bulky disease, depending on the maximal size of lymph 
node mass. in low volume disease, which is defined by 
involved lymph nodes smaller than 3 cm, radiotherapy 
is preferred to chemotherapy. in situations where more 
extensive lymph node involvement is present, chemo-
therapy is preferable. Bulky disease is defined by in-
volved lymph nodes greater than 3 cm, and in this case 
chemotherapy is preferred to radiotherapy1,12. The eu-
ropean society for medical oncology practice guide-
lines recommend chemotherapy or radiotherapy for 
stage iiA, whereas chemotherapy is the preferred op-
tion for stages iiB and iiC18. Recent studies predomi-
nantly recommend chemotherapy for stage iiA due to 
the same relapse rates for chemotherapy and radio-
therapy. Accordingly, chemotherapy is becoming a 
more commonly utilized modality for stage iiA as it is 
for stages iiB and iiC17,19.
After completing the initial therapy, patients are 
evaluated with serum tumor markers and positron 
emission tomography/computed tomography (PeT/
CT) scan. it should be done 6-8 weeks after comple-
tion of chemotherapy to reduce the incidence of false-
positive results. Patients with complete response to 
primary treatment need only surveillance. in cases 
where residual retroperitoneal mass is metabolically 
active, greater than 3 cm, with normal levels of tumor 
markers, there is a higher possibility of residual semi-
noma. A biopsy of residual mass should be considered 
before decision on further treatment option. Post-
chemotherapy retroperitoneal lymph node dissection 
(PC-RPlnD) is difficult to perform in case of pure 
seminoma due to desmoplastic reaction and adherence 
to main blood vessels. in cases of biopsy proven resid-
ual viable seminoma, salvage treatment (chemotherapy 
or radiotherapy) is indicated, while surveillance is 
preferable otherwise. in patients with positive PeT/
CT scan and rising tumor markers, the option is sal-
vage chemotherapy12,18.
Non-seminoma stage I
stage i is defined as a tumor limited to the testis, 
without retroperitoneal lymph node involvement or 
visceral metastases and without increased postorchiec-
tomy serum tumor markers at primary diagnosis. 
About 70% of patients are diagnosed at this stage. The 
overall relapse rate is 30% following orchiectomy. This 
means that 70% of patients are cured by orchiectomy 
alone, and by receiving adjuvant treatment they would 
be unnecessarily exposed to the potential adverse 
events20.
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The investigated risk factors for predicting disease 
relapse include the presence of lymphovascular inva-
sion and the predominant subtype of embryonal carci-
noma in the orchiectomy histologic specimen. Because 
of inconclusive data, predominant embryonal carcino-
ma as a risk factor is not accepted in routine practice. 
Based on the absence or presence of lymphovascular 
invasion, stage i non-seminoma can be divided into 
low-risk stage iA and high-risk stage iB. The relapse 
rate is 15%-20% in stage iA and 40%-50% in stage iB 
without adjuvant treatment2.
following orchiectomy, there are 3 recommended 
options for the management of stage i non-seminoma, 
including active surveillance, adjuvant chemotherapy 
with 1-2 cycles of chemotherapy with PeB protocol, 
or primary nerve-sparing retroperitoneal lymph node 
dissection (p-RPlnD). each option has a cure rate of 
99%20. At our Referral Center, as in other european 
high-volume centers, the preferred option for stage iA 
is active surveillance and for stage iB adjuvant chemo-
therapy with 1 cycle of PeB protocol.
Adjuvant chemotherapy is associated with the low-
est risk of disease recurrence (1%-5%) among the 3 
treatment options. The main disadvantage is the toxic-
ity risk, which is related to the number of PeB proto-
col cycles. some findings confirm that applying 1 in-
stead of 2 cycles of adjuvant PeB chemotherapy sig-
nificantly reduces toxicity without a major increase in 
the risk of relapse (90%-95%)21,22. if only 1 cycle of 
PeB chemotherapy is planned, chest radiography with 
tumor markers within 1 week and abdominal com-
puted tomography within 4 weeks before treatment 
are necessary to confirm that the patient is still in stage 
i. The recommendations concerning treatment options 
differ among high-volume centers. The preferred op-
tion for stage iA is active surveillance, and the alterna-
tive options are p-RPlnD and chemotherapy. The 
preferred option for stage iB is chemotherapy, and the 
alternative options are p-RPlnD and active surveil-
lance9. Advantages of p-RPlnD include reduction in 
the need for chemotherapy, complete staging of the 
retroperitoneum, minimized relapse rates in the retro-
peritoneum, and reduced period of only 1 year of ra-
diological monitoring after negative p-RPlnD. The 
p-RPlnD is a therapeutic option in the case of occult 
stage ii, especially if chemoresistant teratoma is found. 
some experts even consider p-RPlnD as the pre-
ferred option for patients with teratoma and somatic 
transformation in primary tumor18,20. Although it is 
not frequently used today, p-RPlnD is an option for 
patients who refuse chemotherapy treatment and do 
not want to be in surveillance program, especially if 
they have a 50% risk of relapse2,9. Active surveillance is 
rarely offered to patients in stage iB because of higher 
relapse rates, with good compliance as a critical issue 
when this treatment modality is commenced. Those 
who experience relapse during active surveillance pro-
gram should be treated with chemotherapy9.
Non-seminoma stage II
stage ii is defined as a tumor that involves the tes-
tis and retroperitoneal lymph nodes, without visceral 
metastases and with normal or raised postorchiectomy 
serum tumor markers at primary diagnosis. it is di-
vided depending on the size of involved lymph nodes 
in stages iiA (nodes <2 cm), iiB (nodes 2-5 cm) and 
iiC (nodes >5 cm)12. for stage iiC, there is a universal 
consensus about the indication for postorchiectomy 
chemotherapy with 3 cycles of PeB protocol or 4 cy-
cles of Pe protocol. on the contrary, there are some 
differences among high-volume centers concerning 
optimal choice of therapy for stages iiA and iiB, 
which depends on the level of postorchiectomy tumor 
markers1. for stage iiA with negative tumor markers, 
the european and nCCn guidelines recommend 
close follow up of the suspected lymph node involve-
ment. in case of volume progression, treatment op-
tions can be p-RPlnD or chemotherapy with 3 cycles 
of PeB protocol or 4 cycles of Pe protocol. in case of 
positive tumor markers, treatment options are the 
above-mentioned chemotherapeutic protocols. for 
stage iiB with negative tumor markers and surgically 
manageable lymph node involvement, the treatment 
option in highly selected cases can be p-RPlnD. in 
all other cases, the treatment option is chemotherapy, 
as mentioned above12,18.
After primary treatment with p-RPlnD, adjuvant 
chemotherapeutic treatment should be considered de-
pending on the number and size of positive lymph 
nodes. After primary treatment with chemotherapy, 
patients are evaluated by serum tumor markers and ra-
diological imaging. if complete remission is achieved, 
which means negative tumor markers and retroperito-
neal lymph nodes smaller than 1 cm, no further treat-
ment is needed. in case of negative tumor markers and 
residual lymph nodes greater than 1 cm, bilateral PC-
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RPlnD should be performed 1,2. PC-RPlnD is di-
agnostically important to differentiate the type of tu-
mor mass, and in case of teratoma it is the therapeutic 
option since teratoma is chemo- and radio-resistant. 
in PC-RPlnD histology specimens, necrosis can be 
found in 40%-50%, teratoma in 35%-40% and viable 
germ cell carcinoma in 10%-15% of cases23. only in 
case of viable germ cell carcinoma, further adjuvant 
treatment with 2 cycles of conventional chemotherapy 
should be considered12. some studies have shown the 
existence of residual teratoma in subcentimeter retro-
peritoneal nodes following chemotherapy, but PC-
RPlnD on such lymph nodes did not improve the 
overall outcome24.
Seminoma and non-seminoma stage III
stage iii is defined as a tumor that has spread to 
distant lymph nodes or to any other organ. After the 
new risk stratification model was published by the in-
ternational germ Cell Cancer Collaborative group 
(igCCCg) in 1997, treatment guideline has been tai-
lored accordingly. The model classifies patients with 
advanced disease into good, intermediate and poor 
prognosis groups based on the level of tumor markers 
and the location of primary and metastatic germ cell 
tumor1.
Primary treatment of good-risk disease
About 60% of all metastatic cases are classified as 
good-risk disease, with 5-year overall survival rate of 
91%. seminoma stages iiiA and iiiB and non-semi-
noma stage iiiA fall into that category. following or-
chiectomy, the preferred regimen for good-risk pa-
tients is 3 cycles of PeB protocol, which showed the 
same cure benefit as 4 cycles, but with significant re-
duction of toxicity13. for patients who cannot receive 
bleomycin, treatment option is 4 cycles of Pe protocol. 
Although some trials showed advantages of treatment 
with 3 cycles of PeB protocol over 4 cycles of Pe pro-
tocol, the results were not statistically significant. The 
cure rate with chemotherapy is about 90%11,13.
Primary treatment of intermediate/poor-risk disease
About 26% of all metastatic cases are classified as 
intermediate-risk disease with 5-year overall survival 
rate of 79%, and about 14% of metastatic cases are 
classified as poor-risk with 5-year overall survival rate 
of 48%. seminoma stage iiiC and non-seminoma 
stage iiiB fall into intermediate risk, and non-semino-
ma stage iiiC falls into poor risk category.
The preferred postorchiectomy regimen for those 
patients is 4 cycles of PeB protocol. in patients for 
whom bleomycin is not acceptable, treatment option is 
4 cycles of cisplatin, ifosfamide and etoposide (Pei 
protocol). There was no statistically significant differ-
ence in the outcome compared to 4 cycles of PeB pro-
tocol, but it caused greater myelotoxicity and genito-
urinary toxicity. granulocyte colony-stimulating fac-
tor support is recommended whenever Pei protocols 
are chosen. A combination of cisplatin, ifosfamide and 
paclitaxel (TiP protocol) has also shown promising 
 efficacy as first-line therapy in intermediate/poor 
risk patients. There is an ongoing phase 2 trial com-
paring PeB and TiP protocols in those patients 
(nCT01873326)11,13. The cure rate for intermediate 
risk patients treated by chemotherapy is about 80% 
and for poor-risk patients 50%-60%1. High-dose che-
motherapy (HDCT) followed by autologous stem cell 
transplantation (AsCT) as the first-line therapy in in-
termediate/poor-risk patients did not show survival 
advantage over standard treatment with PeB or Pei 
protocol, and thus it is not recommended in routine 
use. some investigators think it should be considered 
in selected poor-risk patients with unsatisfactory tu-
mor marker decline after first or second cycle of PeB 
chemotherapy, those with initial brain metastases and 
patients with mediastinal primary tumor1,13. After pri-
mary treatment with chemotherapy, patients with 
non-seminoma are evaluated with serum tumor mark-
ers and computed tomography imaging. if complete 
remission is achieved, no further treatment is needed. 
in case of negative tumor markers and residual disease, 
all sites of residual retroperitoneal and extraperitoneal 
disease should be surgically removed. unlike lung, liver 
and neck disease, the role of surgery in patients with 
brain metastasis is less common because of the efficacy 
of new radiation techniques combined25. Patients with 
stage iii seminoma are evaluated with tumor markers 
and PeT/CT scan 6-8 weeks after primary treatment 
with chemotherapy. Depending on the results, further 
procedure is similar as in stage ii seminoma1,2.
Stage IS seminoma and non-seminoma
stage is is defined as raised postorchiectomy mark-
ers without radiological evidence of disease. Before 
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starting the treatment, other causes of raised tumor 
markers must be excluded. elevated levels of bHCg 
can be seen in marijuana users and in patients with 
mononucleosis, or because of cross reactivity with lu-
teinizing hormone, while increased AfP can be a sign 
of liver disease26. sustained rise in tumor marker levels 
is an indication for salvage chemotherapy with the ex-
ception of isolated high lDH, as it can be elevated in 
various medical conditions. stage is falls into good-
risk category and patients with non-seminoma are 
treated with 3 cycles of PeB protocol or 4 cycles of Pe 
protocol. The preferred treatment is chemotherapy be-
cause of the high probability of disease dissemination. 
stage is seminoma is a rare condition and patients are 
treated with primary radiotherapy12.
Salvage Treatment of Relapsed  
and Progressive Germ Cell Tumors
up to 30% of patients will have relapse or progres-
sive disease after first-line cisplatin based chemothera-
py, which is diagnosed during post-treatment follow-
up as an increase in tumor marker levels or/and radio-
graphic progression11. in case of isolated tumor marker 
increase and absence of radiographic progression, re-
lapse in brain or second primary in the contralateral 
testis must be excluded. other causes of raised tumor 
markers should also be ruled out26.
The choice of first salvage treatment/second-line 
therapy is still a matter of debate. There are two salvage 
approaches, conventional-dose chemotherapy (CDCT) 
and HDCT followed by AsCT. Determining when to 
treat with CDCT or with HDCT has been investi-
gated throughout the last three decades with predomi-
nantly retrospective analyses, which showed possible 
benefit from HDCT compared to CDCT. The only 
prospective trial that compared CDCT and HDCT in 
first salvage treatment failed to prove any significant 
difference13,27,28. The nCCn guidelines recommend 
CDCT for patients with favorable prognostic factors 
(low volume of disease, low tumor markers, complete 
response to first-line chemotherapy) and high-dose 
programs for patients with unfavorable prognostic fac-
tors12. The international Prognostic factor study 
group categorizes relapsed patients into five prognos-
tic groups, from very low-risk to very high-risk group. 
Accordingly, some investigators propose the use of 
HDCT followed by AsCT only in high-risk groups, 
whereas others propose it in all groups except for the 
very low-risk group1,13. Currently, a prospective ran-
domized phase 3 trial (TigeR) is comparing CDCT 
with HDCT. The results should provide answer about 
the most efficient first salvage approach and elucidate 
which risk group requires HDCT followed by AsCT 
as first salvage treatment11,13.
Three chemotherapy options in CDCT include the 
TiP protocol, the combination of cisplatin, ifosfamide 
and vinblastine (VeiP protocol) and Pei protocol in a 
rare subgroup of patients who did not receive etopo-
side as part of first-line therapy26,29. There are no head-
to-head studies comparing these three protocols, but 
TiP protocol has become the preferred regimen owing 
to better results of durable complete response as com-
pared to VeiP protocol11. The geTug phase ii trial 
incorporated gemcitabine in cisplatin and ifosfamide 
combination for the first time. The so-called giP pro-
tocol showed efficacy as first salvage therapy, especially 
in patients with preexisting neuropathy13,29.
A second salvage option/third-line therapy is 
HDCT, including high doses of carboplatin and eto-
poside. first choice of HDCT regimen is the protocol 
which consists of 2 cycles of citoreductive therapy and 
stem cell mobilization with paclitaxel and ifosfamide, 
followed by 3 cycles of high dose chemotherapy with 
carboplatin and etoposide (Ce) with stem cell trans-
plantation. Another choice is citoreductive therapy 
and stem cell mobilization with Pei protocol, fol-
lowed by 2 cycles of high dose Ce regimen and sup-
ported with stem cell transplantation13,26,29. After first 
salvage treatment, secondary resections of non-semi-
noma residual masses greater than 1 cm are mandatory 
to improve treatment outcome13.
Relapses after the first salvage treatment are very 
challenging to treat due to cisplatin resistance. Therapy 
options for second salvage treatment/third-line thera-
py are combinations of gemcitabine and oxaliplatin, 
gemcitabine and oxaliplatin together with paclitaxel 
and gemcitabine with paclitaxel for patients who did 
not receive prior paclitaxel therapies13,26. salvage sur-
gery is sometimes needed in combination with che-
motherapy if there is a single site of residual disease. 
Depending on patient performance status and comor-
bidities, some investigators offer HDCT with AsCT 
as second salvage therapy29. late relapse is defined as a 
disease relapse two years after finishing the initial che-
motherapeutic treatment. management is very chal-
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lenging due to more aggressive histology and develop-
ment of chemoresistant clones encouraged with previ-
ous chemotherapeutic treatment. it is a distinct clini-
cal entity and occurs in about 2%-3% of survivors30. 
non-seminomas are difficult to cure with only salvage 
chemotherapy because of higher rates of teratoma ex-
isting in relapsed masses, sometimes with somatic ma-
lignant differentiation. This fact makes a combination 
of chemotherapy and surgical resection the preferred 
option of treatment, if it is technically feasible. semi-
nomas should be treated with chemotherapy alone. 
more than 30% of late relapses may occur more than 
10 years after the primary treatment and there is a 
question of lifelong follow-up in patients with 
gCTC31.
All the above mentioned was about patients who 
experience relapse after achieving complete response 
to primary treatment with cisplatin based chemother-
apy. Relapsed patients whose primary treatment did 
not include cisplatin based chemotherapy, but were 
managed with postorchiectomy active surveillance, ad-
juvant treatment with radiotherapy or p-RPlnD, 
should be treated per risk status published by the 
igCCCg group12.
Special Considerations in Treatment Plan
Somatic type malignancy
it is known that 2.7%-8.6% of non-seminomas 
have non-germ cell components. The most common 
ones are sarcomas, primitive neuroectodermal tumors 
(PneT), carcinomas and hematologic malignancies. 
Those somatic-type malignancies are transformed 
from pluripotent teratoma cells and are in most cases 
chemoresistant. The prognosis of such tumors is very 
poor despite aggressive surgical resection combined 
with chemotherapy. Cisplatin based chemotherapy is 
directed to the germ-cell histology subgroup and re-
peated surgical treatment is directed to somatic com-
ponent. Treatment in high-volume centers with multi-
disciplinary approach is crucial32. in case of PneTs 
there are some attempts to improve treatment with 
surgical resections combined with chemotherapy in 
the adjuvant and metastatic setting. The used combi-
nation is cyclophosphamide, doxorubicin and vinblas-
tine alternating it with ifosfamide and etoposide, as it 
is thought that peripheral PneTs are part of ewing 
sarcoma family33.
Choriocarcinoma
up to 8% of non-seminomas contain a choriocarci-
noma component, and 0.2%-0.6% are pure choriocar-
cinomas. Choriocarcinomas arise from extraembryo-
nal differentiation and because of trophoblastic phe-
notype they secrete high levels of bHCg7. Because of 
rapid hematogenous spread to multiple organs (brain, 
lungs, liver, etc.) with intratumoral bleeding that can 
be rapidly fatal, those patients should be treated in 
high-volume centers and treatment strategy must be 
individualized for every patient. in cases of high-vol-
ume disease, chemotherapy should not be delayed be-
cause of orchiectomy or sperm banking. immediate 
chemotherapy improves survival. in cases of lung me-
tastases, bleomycin should not be given in the first cy-
cle because of potential respiratory failure and first 
cycle with Pe protocol should be shortened in unsta-
ble patient to avoid complications of rapid tumor lysis 
syndrome34.
Conclusion
After the introduction of cisplatin based chemo-
therapeutic protocols alongside advances in post-
chemotherapy surgical techniques and radiation, tes-
ticular cancer has become a model of curable cancer. 
The general success of treatment is always a result of 
collaboration within a multidisciplinary team. With a 
myriad of therapeutic options appearing on the hori-
zon, it is of utmost importance to thoroughly present 
all the advantages and disadvantages of a particular 
option to the patient. Adhering to that premise, we 
can achieve maximal objective response and offer the 
opportunity of longstanding high quality of life.
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sažetak
liJeČenJe geRminATiVnog RAKA TesTisA
A. Koši Kunac, M. Gnjidić, Z. Antunac Golubić i M. Gamulin
germinativni rak testisa je maligna novotvorina podrijetla primordijalne zametne stanice. iako čini oko 1% svih malignih 
novotvorina muškaraca, najčešći je malignom mlađe muške populacije s najvećom incidencijom u dobi od 15 do 35 godina. 
incidencija raka testisa povećala se globalno posljednjih nekoliko desetljeća, s prosječnim porastom u incidenciji od 7% 
 godišnje u Hrvatskoj u razdoblju od 1983. do 2007. godine. s obzirom na histološku sliku, germinativni rak testisa dijeli se 
na seminome i neseminome koji se razlikuju u načinu liječenja i odgovoru na terapiju. unatoč porastu u incidenciji, obeća-
vajuća okolnost je da je rak testisa postao model izlječivog tumora. Zbog napretka u dijagnostičkim postupcima, sofisticiranih 
tehnika zračenja, a osobito uvođenja kemoterapijskih protokola baziranih na platini zajedno s naprednim postkemoterapij-
skim kirurškim tehnikama, izlječivost se očekuje u oko 95% svih dijagnosticiranih bolesnika s rakom testisa i oko 70% bole-
snika s uznapredovalom bolešću. u ovom preglednom radu usredotočit ćemo se na strategije liječenja germinativnog raka 
testisa.
Ključne riječi: Germinativni rak testisa; Seminom; Neseminom; Liječenje
